A link between integrins and MMPs in angiogenesis

Fibrinolysis and Proteolysis

Volumn 13, Issue 6, 1999, Pages 226-238

  Silletti, S ^a,b   Cheresh, D A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; MATRIX METALLOPROTEINASE;

ANGIOGENESIS; BINDING SITE; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033497124     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2000.0042     Document Type: Review

References (103)

1. Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol 1989; 109: 317-330.
2. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochem Biophys Acta 1990; 1032: 89-118.
3. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 1153-1155.
4. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188.
5. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
6. Hynes RO. Integrins. Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
7. Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5.
8. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEBJ 1994; 8: 929-938.
9. Polverini PJ. Cellular adhesion molecules. Newly identified mediators of angiogenesis. Am J Pathol 1996; 148: 1023-1029.
10. Enenstein J, Walesh NS, Kramer RH. Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992; 203: 499-503.
11. Murphy JF, Bordet J-C, Wyler B et al. The vitronectin receptor (αvβ3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to endothelial cells. Biochem J 1994; 304: 537-542.
12. Enenstein J, Kramer RH. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol 1994; 103: 381-386.
13. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569-571.
14. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. αvβ3 integrin expression in normal and atherosclerotic artery. Circ Res 1995; 77: 1129-1135.
15. Clark RAF, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of αvβ3 on vascular cells during wound repair. Am J Pathol 1996; 148: 1407-1421.
16. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995; 270: 1500-1502.
17. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995; 108: 2655-2661.
18. Brooks PC, Montgomery AMP, Rosenfeld M et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
19. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
20. Mitjans F, Sander D, Adán J et al. An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108: 2825-2838.
21. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell 1998; 95: 507-519.
22. Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995; 14: 908-917.
23. Stetler-Stevenson WG, Corcoran ML. Tumor angiogenesis: Functional similarities with tumor invasion. EXS 1997; 79: 413-418.
24. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-735.
25. Basbaum CB, Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996; 8: 731-738.
26. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJA, van Hinsbergh VWM. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. BiochemJ 1993; 296: 803-809.
27. Jackson CJ, Nguyen M. Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 1997; 29: 1167-1177.
28. Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998; 273: 3604-3610.
29. Foda HD, George S, Conner C, Drews M, Tompkins DC, Zucker S. Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type metalloproteinase. Lab Invest 1996; 74: 538-545.
30. Lewalle JM, Manaut C, Pichot B, Cataldo D, Baramova E, Foidart JM. Plasma membrane-dependent activation of gelatinase A in human endothelial cells. J Cell Physiol 1995; 165: 475-483.
31. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 1995; 92: 1307-1311.
32. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42.
33. McLaughlin L, Weiss JB. Endothelial-cell-stimulating angiogenesis factor (ESAF) activates progelatinase A (72 kDa type IV collagenase), prostromelysin 1 and procollagenase and reactivates their complexes with tissue inhibitors of metalloproteinases: role for ESAF in non-inflammatory angiogenesis. Biochem J 1996; 317: 739-745.
34. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151: 1105-1113.
35. Brasier AR, Jamaluddin M, Casola A, Duan W, Shen Q, Garofalo RP. A promoter recruitment mechanism for tumor necrosis factor-α-induced interleukin-8 transcription in type II pulmonary epithelial cells. J Biol Chem 1998; 273: 3551-3561.
36. Kurazaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 1998; 5: 673-677.
37. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-1051.
38. Valente P, Fassina G, Melchiori A et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998; 75: 246-253.
39. Wilson MJ, Sinha AA. Human prostate tumor angiogenesis in nude mice: metalloproteinase and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells. Anat Rec 1997; 249: 63-73.
40. Tyagi SC, Kumar S, Cassatt S, Parker JL. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Can J Physiol Pharmacol 1996; 74: 983-995.
41. Pauly RR, Passiniti A, Bilato C et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994, 75: 41-54.
42. Strauss BH, Robinson R, Batchelor WB et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996; 79: 541-550.
43. Kinoh H, Sato H, Tsunezuka Y et al. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 1996; 109: 953-959.
44. Okada A, Tomasetto C, Lutz Y, Bellocq JP, Rio MC, Basset P. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol 1997; 137: 67-77.
45. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248: 1408-1410.
46. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. Inhibition of angiogenesis by the matrix metalloproteinase inhibitor N-[2R-2-(Hydroxyamidocarbonymethyl)-4-methylpentanopyl)]-L-tryptophan methylamide. Cancer Res 1994; 54: 4715-4718.
47. Anand-Apte B, Pepper MS, Voest E et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Opthalmol 1997; 38: 817-823.
48. Koop S, Khokha R, Schmidt EE et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994; 54: 4791-4797.
49. Seftor RE, Seftor EA, Gehlsen KR et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89: 1557-1561.
50. Bafetti LM, Young TN, Itoh Y, Stack MS. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 1998; 273: 143-149.
51. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky C. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989; 109: 877-889.
52. Larjava H, Lyons JG, Salo T et al. Anti-integrin antibodies induce type IV collagenase expression in keratinocytes. J Cell Physiol 1993; 157: 190-200.
53. Chintala SK, Sawaya R, Gokaslan ZL, Rao JS. Modulation of matrix metalloprotease-2 and invasion in human glioma cells by α3β1 integrin. Cancer Lett 1996; 103: 201-208.
54. Huhtula P, Humphries MJ, McCarthyJB, Tremble PM, Werb Z, Damsky CH. Cooperative signaling by α5β1 and α4β1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol 1995; 129: 867-879.
55. Monsky WL, Kelly T, Lin C-Y et al. Binding and localization of Mr 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res 1993; 53: 3159-3164.
56. Okada Y, Morodomi T, EnghildJJ et al. Matrix metalloproteinase-2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymatic properties. Eur J Biochem 1990; 194: 721-730.
57. Murphy I, Willenbrock F, Ward RV et al. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis but is essential for membrane activation and modulates interactions with tissue inhibitor of metalloproteinases. J Biochem 1992; 283: 637-641.
58. Strongin AY, Marmer BL, Grant GA, Goldberg GI. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem 1993; 268: 14033-14039.
59. Butler GS, Butler MJ, Atkinson SJ et al. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. J Biol Chem 1998; 273: 871-880.
60. Kinoshita T, Sato H, Okada A et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998; 273: 16098-16103.
61. Zucker S, Drews M, Conner C et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998; 273: 1216-1222.
62. Li H, Bauzon DE, Xu X, Tschesche H, Cao J, Sang QA. Immunological characterization of cell surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Mol Carcinog 1998; 22: 84-94.
63. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271: 9135-9140.
64. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. J Biol Chem 1996; 271: 17119-17123.
65. Strongin AY, Collier I, Bannikov G, Manner BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 1995; 270: 5331-5338.
66. Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y, Negase H. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem 1998; 273: 24360-24367.
67. Howard EW, Banda MJ. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. J Biol Chem 1991; 266: 17972-17977.
68. Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 1997; 272: 29975-29983.
69. Butler GS, Will H, Atkinson SJ, Murphy G. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem 1997; 244: 653-657.
70. Shofuda K, Yasumitsu H, Nishihashi A, Miki K, Miyazaki K. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MTS-MMPs with and without transmembrane domain. J Biol Chem 1997; 272: 9749-9754.
71. Shofuda K, Moriyama K, Nishihashi A et al. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of progelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem 1998; 124: 462-470.
72. Deryugina E, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998; 58: 3743-3750.
73. Lichte A, Kolkenbrock H, Tschesche H. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2. FEBS Lett 1996; 397: 277-282.
74. Crabbe T, Ioannou C, Docherty AJP. Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur J Biochem 1993; 218: 431-438.
75. Deryugina EI, Bourdon MA, Luo G-X, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 1997; 110: 2473-2482.
76. Deryugina EI, Luo G-X, Reisfeld RA, Bourdon MA, Strongin A. Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 1997; 17: 3201-3210.
77. Mazzieri R, Masiero L, Zanetta L et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997; 16: 2319-2332.
78. Baramova EN, Bajou K, Remacle A et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEES Lett 1997; 405: 157-162.
79. Zucker S, Conner C, DiMassmo BI et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 1995; 270: 23730-23738.
80. Byzova TV, Plow EF. Activation of αvβ3 on vascular cells controls recognition of prothrombin. J Cell Biol 1998; 143: 2081-2092.
81. Zucker S, Mirza H, Conner CE et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998; 75: 780-786.
82. Puente XS, Pendas AM, Llano E, Valesco G, Lopez-Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56: 944-949.
83. Okamura Y, Sato H, Seiki M, Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett 1997; 402: 181-184.
84. Filardo EJ, Brooks PC, Deming SL, Damsky C, Cheresh DA. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol 1995; 130: 441-450.
85. Brooks PC, Strömblad S, Sanders LC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996; 85: 683-693.
86. Montgomery AMP, Reisfeld RA, Cheresh DA. Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91: 8856-8860.
87. Strömblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CYP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest 1996; 98: 426-433.
88. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 24: 344-353.
89. Stefanssor S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 1996; 383: 441-443.
90. Brooks PC, Silletti S, von Schalscha T, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
91. Friedlander M, Theesfeld CL, Sugita M et al. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93: 9764-9769.
92. Mehta RJ, Diefenbach B, Brown A et al. Transmembrane-truncated avβ3 integrin retains high affinity for ligand binding: evidence for an 'inside-out' suppressor? Biochem J 1998; 330: 861-869.
93. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
94. Levi E, Fridman R, Miao H-Q, Ma Y-S, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996; 93: 7069-7074.
95. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
96. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997; 337: 195-197.
97. O'Reilley MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
98. O'Reilley MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
99. Clapp C, Torner L, Gutierrez-Ospina G et al. The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin. Proc Natl Acad Sci USA 1994; 91: 10384-10388.
100. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995; 92: 7799-7803.
101. Iruela-Arispe ML, Lane TF, Redmond D et al. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol Biol Cell 1995; 6: 327-343.
102. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 1994; 5: 565-574.
103. Gianelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997; 277: 225-228.